Class III BRAF mutations have a different mutational profile involving N581 or D594 residues and are RAS-dependent, have low or absent BRAF kinase activity and cooperate with concurrent RAS or NF1 mutations; melanomas bearing these mutations are less sensitive to BRAF+MEK inhibitors than melanomas with class II mutations [17]. The gene discussed is NF1; the disease is melanoma.